JP2018531880A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018531880A5 JP2018531880A5 JP2017567056A JP2017567056A JP2018531880A5 JP 2018531880 A5 JP2018531880 A5 JP 2018531880A5 JP 2017567056 A JP2017567056 A JP 2017567056A JP 2017567056 A JP2017567056 A JP 2017567056A JP 2018531880 A5 JP2018531880 A5 JP 2018531880A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- peptide
- configuration
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 127
- 238000000034 method Methods 0.000 claims description 58
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 44
- 239000000203 mixture Substances 0.000 claims description 36
- 239000008194 pharmaceutical composition Substances 0.000 claims description 34
- 239000002202 Polyethylene glycol Substances 0.000 claims description 18
- 229920001223 polyethylene glycol Polymers 0.000 claims description 18
- 241000894006 Bacteria Species 0.000 claims description 17
- 150000001413 amino acids Chemical class 0.000 claims description 16
- 125000000539 amino acid group Chemical group 0.000 claims description 14
- 229920000642 polymer Polymers 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 208000015181 infectious disease Diseases 0.000 claims description 10
- 241000191967 Staphylococcus aureus Species 0.000 claims description 9
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims description 9
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims description 8
- 229930182555 Penicillin Natural products 0.000 claims description 8
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 8
- 108010059993 Vancomycin Proteins 0.000 claims description 8
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 8
- 229960003085 meticillin Drugs 0.000 claims description 8
- 244000005700 microbiome Species 0.000 claims description 8
- 229940049954 penicillin Drugs 0.000 claims description 8
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims description 8
- 229960003165 vancomycin Drugs 0.000 claims description 8
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims description 8
- 241000700605 Viruses Species 0.000 claims description 6
- 230000000249 desinfective effect Effects 0.000 claims description 6
- 230000000813 microbial effect Effects 0.000 claims description 6
- 230000010076 replication Effects 0.000 claims description 5
- 241000193163 Clostridioides difficile Species 0.000 claims description 4
- 241000186427 Cutibacterium acnes Species 0.000 claims description 4
- 241000588655 Moraxella catarrhalis Species 0.000 claims description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 4
- 229960003405 ciprofloxacin Drugs 0.000 claims description 4
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims description 4
- 229960002227 clindamycin Drugs 0.000 claims description 4
- 229940055019 propionibacterium acne Drugs 0.000 claims description 4
- 241000712892 Arenaviridae Species 0.000 claims description 3
- 241000193738 Bacillus anthracis Species 0.000 claims description 3
- 241001502567 Chikungunya virus Species 0.000 claims description 3
- 241000725619 Dengue virus Species 0.000 claims description 3
- 241001115402 Ebolavirus Species 0.000 claims description 3
- 241000194032 Enterococcus faecalis Species 0.000 claims description 3
- 241000710781 Flaviviridae Species 0.000 claims description 3
- 241000606768 Haemophilus influenzae Species 0.000 claims description 3
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 3
- 241000150350 Peribunyaviridae Species 0.000 claims description 3
- 241000700625 Poxviridae Species 0.000 claims description 3
- 241000712907 Retroviridae Species 0.000 claims description 3
- 241000194017 Streptococcus Species 0.000 claims description 3
- 241000710924 Togaviridae Species 0.000 claims description 3
- 239000012620 biological material Substances 0.000 claims description 3
- 229940032049 enterococcus faecalis Drugs 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 241000712461 unidentified influenza virus Species 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 241000710842 Japanese encephalitis virus Species 0.000 claims 1
- 241001115401 Marburgvirus Species 0.000 claims 1
- 241000710772 Yellow fever virus Species 0.000 claims 1
- 241000907316 Zika virus Species 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 229940051021 yellow-fever virus Drugs 0.000 claims 1
- 239000000126 substance Substances 0.000 description 74
- 229910052698 phosphorus Inorganic materials 0.000 description 42
- 230000001580 bacterial effect Effects 0.000 description 11
- 208000035143 Bacterial infection Diseases 0.000 description 7
- 208000022362 bacterial infectious disease Diseases 0.000 description 7
- 230000029812 viral genome replication Effects 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 208000036142 Viral infection Diseases 0.000 description 5
- 230000009385 viral infection Effects 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 150000008574 D-amino acids Chemical class 0.000 description 2
- 241000711950 Filoviridae Species 0.000 description 2
- 150000008575 L-amino acids Chemical class 0.000 description 2
- 229940047650 haemophilus influenzae Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 206010061190 Haemophilus infection Diseases 0.000 description 1
- 206010062204 Moraxella infection Diseases 0.000 description 1
- 208000032536 Pseudomonas Infections Diseases 0.000 description 1
- 208000022338 anthrax infection Diseases 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562184354P | 2015-06-25 | 2015-06-25 | |
| US62/184,354 | 2015-06-25 | ||
| PCT/SG2016/050291 WO2016209173A1 (en) | 2015-06-25 | 2016-06-24 | Broad-spectrum anti-infective peptides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019184326A Division JP2020040950A (ja) | 2015-06-25 | 2019-10-07 | 広域スペクトル抗感染ペプチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018531880A JP2018531880A (ja) | 2018-11-01 |
| JP2018531880A5 true JP2018531880A5 (enExample) | 2019-08-08 |
| JP6768012B2 JP6768012B2 (ja) | 2020-10-14 |
Family
ID=57586064
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017567056A Active JP6768012B2 (ja) | 2015-06-25 | 2016-06-24 | 広域スペクトル抗感染ペプチド |
| JP2019184326A Pending JP2020040950A (ja) | 2015-06-25 | 2019-10-07 | 広域スペクトル抗感染ペプチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019184326A Pending JP2020040950A (ja) | 2015-06-25 | 2019-10-07 | 広域スペクトル抗感染ペプチド |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10351604B2 (enExample) |
| EP (1) | EP3313862B9 (enExample) |
| JP (2) | JP6768012B2 (enExample) |
| KR (1) | KR20180037185A (enExample) |
| CN (1) | CN107922461A (enExample) |
| AU (1) | AU2016281477A1 (enExample) |
| BR (1) | BR112017028190A2 (enExample) |
| CA (1) | CA2989399A1 (enExample) |
| HK (1) | HK1248248A1 (enExample) |
| MX (1) | MX2017016227A (enExample) |
| SG (1) | SG10201912866RA (enExample) |
| WO (1) | WO2016209173A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1248248A1 (zh) | 2015-06-25 | 2018-10-12 | 南洋理工大学 | 广谱抗感染肽 |
| EP3843701B1 (en) | 2018-08-30 | 2024-02-21 | Osel, Inc. | Bacteriocins to improve vaginal colonization of hydrogen peroxide producing lactobacillus for female reproductive health |
| WO2022020766A1 (en) * | 2020-07-24 | 2022-01-27 | Oak Crest Institute Of Science | Materials and methods for the prevention and treatment of viral respiratory diseases |
| WO2022220749A1 (en) * | 2021-04-13 | 2022-10-20 | Nanyang Technological University | Anti-viral peptide compositions and methods to improve biological activity thereof |
| US20240197814A1 (en) * | 2021-04-27 | 2024-06-20 | Oak Crest Institute Of Science | Materials and methods for the prevention and treatment of viral diseases |
| CN117756904B (zh) * | 2023-12-22 | 2024-05-24 | 潍坊医学院 | 一种订书肽及其应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7326536B2 (en) | 2001-05-03 | 2008-02-05 | Eli Lilly And Company | Agents for treatment of HCV and methods of use |
| EP1357127A1 (de) * | 2002-04-10 | 2003-10-29 | Immusystems GmbH | CD4+ T-Lymphozyten spezifische Hepatitis C Virus-Epitope |
| EP1537418A2 (en) * | 2002-09-13 | 2005-06-08 | Intercell AG | Method for isolating hepatitis c virus peptides |
| AU2003263653A1 (en) * | 2002-09-27 | 2004-04-19 | Daewoong Co., Ltd. | A vaccine enhancing the protective immunity to hepatitis c virus using plasmid dna and recombinant adenovirus |
| RU2006144714A (ru) * | 2004-05-17 | 2008-06-27 | Чирон Корпорейшн (Us) | Усеченный ns5 домен вируса гепатита с и содержащие его слитые белки |
| CA2624153A1 (en) | 2005-09-29 | 2007-04-12 | The Scripps Research Institute | Viral peptides and their use to inhibit viral infections against viruses of the flaviridae family |
| WO2008133759A2 (en) * | 2007-01-10 | 2008-11-06 | The Scripps Research Institute | Antiviral peptides |
| EP3159352B1 (en) * | 2007-03-28 | 2023-08-02 | President and Fellows of Harvard College | Stitched polypeptides |
| US8728793B2 (en) | 2007-07-19 | 2014-05-20 | The Board Of Trustees Of The Leland Stanford Junior University | Amphipathic alpha-helical peptide compositions as antiviral agents |
| EP2237787A4 (en) | 2008-01-03 | 2012-03-21 | Massachusetts Inst Technology | DECOY-INFLUENZA THERAPIES |
| US8586707B2 (en) | 2008-09-16 | 2013-11-19 | The Research Foundation Of State University Of New York | Stapled peptides and method of synthesis |
| RU2447899C2 (ru) | 2010-05-27 | 2012-04-20 | Михаил Валентинович Филатов | Композиция для лечения гепатита с и способ лечения гепатита с |
| EP2763532B1 (en) * | 2011-10-05 | 2018-09-19 | The Board of Trustees of the Leland Stanford Junior University | Pi-kinase inhibitors with broad spectrum anti-infective activity |
| HK1248248A1 (zh) | 2015-06-25 | 2018-10-12 | 南洋理工大学 | 广谱抗感染肽 |
-
2016
- 2016-06-24 HK HK18107687.3A patent/HK1248248A1/zh unknown
- 2016-06-24 MX MX2017016227A patent/MX2017016227A/es unknown
- 2016-06-24 CN CN201680049114.2A patent/CN107922461A/zh active Pending
- 2016-06-24 BR BR112017028190A patent/BR112017028190A2/pt not_active IP Right Cessation
- 2016-06-24 SG SG10201912866RA patent/SG10201912866RA/en unknown
- 2016-06-24 AU AU2016281477A patent/AU2016281477A1/en not_active Abandoned
- 2016-06-24 JP JP2017567056A patent/JP6768012B2/ja active Active
- 2016-06-24 KR KR1020187002411A patent/KR20180037185A/ko not_active Withdrawn
- 2016-06-24 US US15/738,730 patent/US10351604B2/en active Active
- 2016-06-24 WO PCT/SG2016/050291 patent/WO2016209173A1/en not_active Ceased
- 2016-06-24 CA CA2989399A patent/CA2989399A1/en not_active Abandoned
- 2016-06-24 EP EP16814828.6A patent/EP3313862B9/en active Active
-
2019
- 2019-05-23 US US16/421,119 patent/US20200087349A1/en not_active Abandoned
- 2019-10-07 JP JP2019184326A patent/JP2020040950A/ja active Pending
-
2021
- 2021-06-15 US US17/348,593 patent/US11866460B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018531880A5 (enExample) | ||
| Nuti et al. | Antimicrobial peptides: a promising therapeutic strategy in tackling antimicrobial resistance | |
| Kosikowska et al. | Antimicrobial peptides (AMPs) as drug candidates: a patent review (2003–2015) | |
| AU2019222918B2 (en) | Antimicrobial peptides and methods of use thereof | |
| Liu et al. | Multivalent antimicrobial peptides as therapeutics: design principles and structural diversities | |
| US8809262B2 (en) | Multimeric forms of antimicrobial peptides | |
| JP2012176978A5 (enExample) | ||
| RS58980B1 (sr) | Peptidi i njihova upotreba | |
| JP2013509389A5 (enExample) | ||
| JP2017526627A5 (enExample) | ||
| US20220362332A1 (en) | Romo1-derived antimicrobial peptides including lysine substitution and variants thereof | |
| RU2014140231A (ru) | Антимикробные пептиды | |
| JP6066222B2 (ja) | 抗菌ペプチド及びその利用 | |
| JP2020520917A5 (enExample) | ||
| KR20180037185A (ko) | 광범위의 항감염성 펩티드 | |
| KR20160145216A (ko) | 바퀴벌레에서 유래한 항균 펩타이드 페리플라네타신-1 및 그의 조성물 | |
| US9486496B2 (en) | Anti periodontitis-causing microorganism agent and medical or dental materials using the same | |
| Kalimuthu et al. | Antibiotic-peptide conjugation against multi-drug resistant pathogens: a comprehensive review for therapeutics and drug delivery strategies | |
| JP4812347B2 (ja) | 抗菌性ペプチド | |
| JP2020158513A (ja) | 環状抗微生物性擬ペプチド及びその使用 | |
| AU2020302077B2 (en) | Compositions and methods for treatment of fungal infections | |
| JPH05507273A (ja) | Ｄアミノ酸残基を有する生物活性ペプチドの組成物およびそれによる治療方法 | |
| JP2019510519A5 (enExample) | ||
| CN111471093B (zh) | 一种多肽抗生素及其制备方法和用途 | |
| VYAS et al. | An Updated Review on Antimicrobial Peptides as Antibiofilm Agent. |